Abstract
2026 A Phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have